Nuvalent Q3 net loss $19.7M; NVL-520 shows proof-of-concept; $264.5M offering extends runway into H2 2025

Nuvalent, Inc.

2022-Q3 EPS reported -$1.15

Q3 net loss $19.7M ($0.41/sh); cash $240.1M; with $264.5M offering extends runway into H2 2025.
NVL-520 Phase 1 data: no DLTs, activity in heavily pre-treated ROS1+ NSCLC including G2032R and brain metastases.
NVL-655 (ALK inhibitor) enrollment in Phase 1 ALKOVE-1 trial progressing; new preclinical data shows activity against compound mutations.
NVL-330 (HER2 exon 20) preclinical data demonstrates potency, selectivity, brain penetration; potential best-in-class.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.